ABSTRACT
OBJECTIVE: To determine the chronic effects of oral cannabidiol (CBD) use on tear production, intraocular pressure (IOP), and concentration of CBD in tears of healthy dogs. ANIMALS STUDIED: Eighteen healthy research Beagles. PROCEDURES: This was a masked, placebo-controlled, randomized prospective study. Eighteen dogs were randomly assigned to three groups (six dogs per group) based on daily dosage of oral MCT oil (placebo), CBD 5 mg/kg, and CBD 10 mg/kg. Schirmer tear test (STT-1) and IOP were measured twice daily (7 am and 7 pm) every 4 weeks for 36 weeks. Week 36 tears were collected and analyzed for CBD concentrations (ng/mL) using liquid chromatography/mass spectrometry. A mixed linear model was used as the statistical method and p-value <.05 was considered significant. RESULTS: No significant differences were found between placebo vs. 5 mg/kg vs. 10 mg/kg for STT-1 or IOP (AM and PM). CBD was detected in 10 out of 11 (91%) viable tear samples receiving 5 mg/kg or 10 mg/kg dosages. One sample in the 5 mg/kg group had inadequate tear volume for analysis. The CBD concentration in tears was at or below the lower limit of quantification in placebo group, 4.12-11.2 ng/mL for the 5 mg/kg group, and 6.22-152 ng/mL for the 10 mg/kg group. CONCLUSIONS: Long-term administration of oral CBD in healthy research beagles demonstrates a favorable safety profile regarding ocular tolerability. Oral CBD administration does not appear to affect tear production or IOP over a 36-week period. This is the first canine study positively identifying concentrations of CBD in tears following oral administration.
ABSTRACT
OBJETIVO: Medir la cobertura efectiva para once intervenciones de salud en nueve países de América Latina utilizando las encuestas de demografía y salud o registros administrativos que abarcan la salud infantil, de la mujer y el adulto. MATERIAL Y MÉTODOS: Se seleccionaron las intervenciones y se armonizaron definiciones y métodos de cálculo de acuerdo con la información disponible para lograr la comparabilidad entre países. RESULTADOS: Chile es el país con mejores indicadores de coberturas crudas y efectivas, seguido por México y Colombia, y existen brechas importantes entre regiones, departamentos o estados. CONCLUSIONES: La métrica de cobertura efectiva es un indicador sensible que relaciona la necesidad de las intervenciones en salud, su utilización y calidad, lo que permite valorar los programas de salud al aportar datos precisos de dónde y a quién deben dirigirse los recursos y esfuerzos nacionales para que los países alcancen los propósitos y metas planteados.
OBJECTIVE: To measure effective coverage for ll health interventions in Latin America including the children's, women's and adult health, as part of program evaluation. MATERIAL AND METHODS: Interventions were selected; the definitions and calculation methods were harmonized according to the information available to ensure comparability between countries. RESULTS: Chile has better indicators of crude and effective coverage followed by Mexico and Colombia.There are significant gaps between regions, counties or states. CONCLUSIONS: The health metric on effective coverage is a sensitive indicator that links three important aspects: Coverage of health interventions, use of health services, and access to such services. Effective coverage is a good tool to evaluate health programs performance, and also provides data of where and to whom the system should address national efforts and resources to achieve the purposes and goals set.
